Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
about
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerClinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study.STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis.Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancerEvaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trialPrognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms.Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancerPrognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis.Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes.How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients.Therapeutic strategy in unresectable metastatic colorectal cancer.Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy.Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy-single-institution experience.
P2860
Q26748924-47C61C7C-B021-45BB-B59A-B4F2C0EA97A2Q30313248-28C3DB3B-9DE9-472C-9163-4393793F11E5Q33645784-A8ED4EBB-53BA-46D2-9B18-7B93AECB5B3AQ35682543-E5A9E147-90F7-4B57-BB00-3A612325616EQ35970714-B5604161-4964-45A7-ABFF-04FBE11C5BE8Q36724011-507DC708-113F-4916-A35F-E173245AC579Q36797283-2D5B953F-39C4-4021-9C22-356CE392BCF5Q37182219-87C12C6E-6249-4DC8-A660-52171621C5EDQ37457735-1BEC35CB-3983-4D05-89C1-FDF6DB14663FQ37677524-644B3702-2DB4-4357-A3AC-8D845BA264C9Q37744341-85FAEB00-E8F4-44F9-81A7-AAE2FE829140Q38312076-6354408F-B840-405C-B896-E786983477EAQ38487988-8FB61D08-C5AE-4A35-A82D-2FD74C5ED07FQ38647041-3B054843-39A1-4C34-AB8A-65EFCDAE8A3BQ38826639-8E8363A1-B0AE-4D7E-A0FD-D26C868F626BQ38975554-A98FDE7F-6BE7-4070-B482-30AFF975EDCEQ40507543-3F6389C5-D840-4757-AE0D-3BA6F82E126DQ42000639-BC4F92B0-8D8A-43F5-8717-CDFB38CBDD63Q44706440-B0526A26-E810-4E80-8BFE-2799FAF8E849Q47988846-F6283602-CBE2-4136-A167-934AD1AC1EEBQ48136626-1B1DD269-279E-4D7F-9124-9B9DC4CC9FC3Q50973552-75C1D5C3-E6A8-4603-A815-4C1493E5ACAAQ51127921-DC363A22-221D-4FE3-8EAF-72363E50078CQ53666492-09E32AD7-7950-4353-BE82-0522553867BA
P2860
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Simplified prognostic model in ...... orectal cancer: a GERCOR study
@ast
Simplified prognostic model in ...... orectal cancer: a GERCOR study
@en
type
label
Simplified prognostic model in ...... orectal cancer: a GERCOR study
@ast
Simplified prognostic model in ...... orectal cancer: a GERCOR study
@en
prefLabel
Simplified prognostic model in ...... orectal cancer: a GERCOR study
@ast
Simplified prognostic model in ...... orectal cancer: a GERCOR study
@en
P2093
P2860
P1433
P1476
Simplified prognostic model in ...... orectal cancer: a GERCOR study
@en
P2093
Annette K Larsen
Benoist Chibaudel
Christophe Louvet
Christophe Tournigand
Franck Bonnetain
Jérôme Desramé
Leila Bengrine-Lefevre
Luis Teixeira
Pascal Artru
Thierry André
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0039
P577
2011-08-22T00:00:00Z